DNA RNA and Cells

07 Nov 2022 GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers
07 Nov 2022 Calidi Biotherapeutics Presents Promising Pre-Clinical Data from SuperNova-1 (SNV1), a Novel Oncolytic-Cell Based Platform, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)
07 Nov 2022 Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors
07 Nov 2022 Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
06 Nov 2022 Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)
05 Nov 2022 Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting
04 Nov 2022 Ionis announces positive results from fesomersen development program
04 Nov 2022 Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101
04 Nov 2022 4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022
04 Nov 2022 Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes
02 Nov 2022 Decibel Therapeutics Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate DB-OTO
02 Nov 2022 Brexogen's Exosome Therapy for Atopic Dermatitis, 'BRE-AD01' Accepted for Phase 1 Clinical Trials by US FDA
01 Nov 2022 Turnstone Biologics Announces FDA Clearance of IND for TIDAL-01, a Next-Generation TIL Therapy for Solid Tumors
30 Oct 2022 Nuevocor to Present Pre-clinical Data on its Gene Therapy Candidate for LMNA Dilated Cardiomyopathy at American Heart Association Scientific Sessions 2022
27 Oct 2022 Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia
27 Oct 2022 Omega Therapeutics Announces First Patient Dosed in Landmark MYCHELANGELO™ I Trial of OTX-2002 in Hepatocellular Carcinoma and Other Solid Tumor Types Associated with the MYC Oncogene
26 Oct 2022 RZNOMICS Inc. received FDA approval to initiate clinical development of trans-splicing ribozyme-based RNA editing technology in liver cancer patients
26 Oct 2022 Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK
26 Oct 2022 Cellevolve Bio Receives FDA Clearance of IND Application and Orphan Drug Designation for CE-VST01-JC for the Treatment of Progressive Multifocal Leukoencephalopathy (PML)
21 Oct 2022 T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial
20 Oct 2022 Preclinical Data from iECURE’s GTP-506 Demonstrates Potential for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
19 Oct 2022 NKGen Biotech Receives IND Clearance from FDA for SNK02 Allogeneic Natural Killer Cell Therapy for Solid Tumors
19 Oct 2022 Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung Cancer
18 Oct 2022 Kyverna Therapeutics Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis
18 Oct 2022 Kite’s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up